var data={"title":"Donepezil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Donepezil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6068?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=donepezil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Donepezil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162576\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aricept;</li>\n      <li>Aricept ODT [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162577\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aricept;</li>\n      <li>Aricept RDT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162609\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Acetylcholinesterase Inhibitor (Central)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162581\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alzheimer disease:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate: Initial: 5 mg once daily; may increase to 10 mg once daily after 4 to 6 weeks; effective dosage range in clinical studies: 5 to 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate-to-severe: Initial: 5 mg once daily; may increase to 10 mg once daily after 4 to 6 weeks; may increase further to 23 mg once daily after &ge;3 months; effective dosage range in clinical studies: 10 to 23 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dementia associated with Parkinson disease (off-label use):</b> 5 mg once daily; may increase to 10 mg once daily after 4 to 6 weeks; may increase further to 23 mg once daily after the use of 10 mg once daily &ge;3 months (APA [Rabins 2007]); Dubois 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lewy body dementia (off-label use): </b>Initial: 2.5 mg once daily for 2 weeks, then increase to 5 mg once daily. After 4 weeks may further increase dose based on response and tolerability up to 10 mg once daily (Ikeda 2013; Mori 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traumatic brain injury (off-</b>\n      <b>label use):</b> Initial: 5 mg once daily for 2 to 3 weeks, then increase to 10 mg once daily (Kim 2009; Zhang 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vascular dementia (with comorbid Alzheimer disease) (off-label use):</b> See Alzheimer disease dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162582\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. <b>Note:</b> The Canadian labeling recommends a maximum dose of 5 mg once daily in elderly women (&ge;85 years of age) of low body weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15804856\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Limited data suggest severe renal impairment does not adversely affect donepezil clearance. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15804857\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162555\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aricept: 5 mg, 10 mg, 23 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 23 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aricept ODT: 5 mg [DSC], 10 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162541\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F759356\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer at bedtime without regard to food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aricept 23 mg tablet: Swallow whole with water; do <b>NOT</b> crush or chew due to an increased rate of absorption. The 23 mg strength is provided in a unique film-coated formulation different from the 5 mg or 10 mg tablet strengths, which results in an altered pharmacokinetic profile.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aricept ODT: Allow tablet to dissolve completely on tongue and follow with water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162557\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Alzheimer disease:</b> Treatment of mild, moderate, or severe dementia of the Alzheimer type</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725331\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Dementia associated with Parkinson disease; Lewy body dementia; Traumatic brain injury; Vascular dementia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162616\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aricept may be confused with AcipHex, Ascriptin, and Azilect</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162548\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Insomnia (2% to 14%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (3% to 19%; dose related), diarrhea (5% to 15%; dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Accidental injury (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&ge;1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (3%), chest pain (2%), syncope (2%), atrial fibrillation (&ge;1%), bradycardia (&ge;1%), cardiac failure (&ge;1%), ECG abnormality (&ge;1%), edema (&ge;1%), hypotension (&ge;1%), peripheral edema (&ge;1%), vasodilation (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (3% to 10%), pain (3% to 9%), dizziness (2% to 8%), fatigue (1% to 8%), abnormal dreams (3%), hallucination (3%), hostility (3%), depression (2% to 3%), nervousness (1% to 3%), confusion (2%), drowsiness (2%), emotional lability (2%; including crying), personality disorder (2%), abnormal gait (&ge;1%), aggressive behavior (&ge;1%), agitation (&ge;1%), anxiety (&ge;1%), aphasia (&ge;1%), ataxia (&ge;1%), convulsions (&ge;1%), delusions (&ge;1%), irritability (&ge;1%), paresthesia (&ge;1%), restlessness (&ge;1%), vertigo (&ge;1%), wandering (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Ecchymosis (4% to 5%), eczema (3%), dermal ulcer (&ge;1%), diaphoresis (&ge;1%), pruritus (&ge;1%), skin rash (&ge;1%), urticaria (&ge;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight loss (3% to 5%; dose related), hyperlipidemia (2%), dehydration (1% to 2%), glycosuria (&ge;1%), hot flash (&ge;1%), increased lactate dehydrogenase (&ge;1%), increased libido (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Vomiting (3% to 9%; dose related), anorexia (2% to 8%), abdominal pain (&ge;1%), bloating (&ge;1%), constipation (&ge;1%), dyspepsia (&ge;1%), epigastric pain (&ge;1%), fecal incontinence (&ge;1%), gastroenteritis (&ge;1%), gastrointestinal hemorrhage (&ge;1%), sore throat (&ge;1%), toothache (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary incontinence (1% to 3%), urinary frequency (2%), cystitis (&ge;1%), hematuria (&ge;1%), nocturia (&ge;1%), urinary tract infection (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Bruise (2%), hemorrhage (2%), anemia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Fungal infection (&ge;1%), influenza (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle cramps (3% to 8%), back pain (3%), increased creatine phosphokinase (3%), arthritis (1% to 2%), weakness (1% to 2%), bone fracture (&ge;1%), tremor (&ge;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision (&ge;1%), cataract (&ge;1%), eye irritation (&ge;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchitis (&ge;1%), dyspnea (&ge;1%), flu-like symptoms (&ge;1%), increased cough (&ge;1%), pharyngitis (&ge;1%), pneumonia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&le;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, abnormal lacrimation, abnormal vision, abscess, acute rhinitis, albuminuria, alopecia, angina pectoris, apathy, arteritis, arthralgia, arthropathy, asthma, atelectasis, atrophic striae, benign prostatic hypertrophy, blepharitis, breast fibroadenosis, cachexia, cardiomegaly, cellulitis, cerebral hemorrhage, cerebral infarction, cerebral ischemia, cerebrovascular accident, chills, cholecystitis, cholelithiasis, conjunctival hemorrhage, conjunctivitis, convulsions, decreased libido, deep vein thrombosis, dementia, dermatitis, diabetes mellitus, diverticulitis, duodenal ulcer, dysarthria, dysgeusia, dysphagia, dysphoria, dysuria, emotional disturbance, eosinophilia, epigastric distress, epistaxis, eructation, erythema, erythrocytopenia, esophagitis, euphoria, extrapyramidal reaction, facial edema, fasciculations, fibrocystic breast changes, first degree atrioventricular block, flatulence, fungal dermatitis, gastritis, gastric ulcer, gingivitis, glaucoma, goiter, gout, hearing loss, heart block, hemiplegia, hemolytic anemia, hemorrhoids, hepatitis, hernia, herpes zoster, hiatal hernia, hirsutism, hyperbilirubinemia, hyperglycemia, hyperkeratosis, hypersensitivity reaction, hypertonia, hypokalemia, hypokinesia, hyponatremia, hypoproteinemia, hypoxia, increased appetite, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased post-void residual urine volume, increased serum ALT, increased serum AST, increased serum creatinine, increased serum transaminases, increased thirst, intestinal obstruction, intracranial hemorrhage, iron deficiency anemia, irritable bowel syndrome, jaundice, leg cramps, leukocytosis, localized coldness, malaise, mastitis, melena, motion sickness, muscle spasm, myalgia, myasthenia, myocardial infarction, neuralgia, neurodermatitis, neuroleptic malignant syndrome, night sweats, nystagmus, orthostatic hypotension, osteoporosis, otalgia, otitis externa, otitis media, pacing, pancreatitis, paranoia, peptic ulcer disease, periodontal abscess, periodontitis, periorbital edema, peripheral vascular disease, pernicious anemia, pleurisy, polydipsia, post nasal drip, prolonged Q-T interval on ECG, psoriasis, pulmonary congestion, pyelonephritis, pyuria, rectal hemorrhage, renal failure, retinal hemorrhage, rhabdomyolysis, rhinitis, seeing spots, sensation of cold, sepsis, severe depression, sialorrhea, skin discoloration, sleep apnea, snoring, supraventricular extrasystole, supraventricular tachycardia, thrombocythemia, thrombocytopenia, tinnitus, tongue edema, tonic-clonic seizures, torsades de pointes, transient ischemic attacks, urinary urgency, uterine hemorrhage, vaginitis, vasodilation, ventricular premature contractions, ventricular tachycardia, vertigo, vesiculobullous dermatitis, weight gain, wheezing, xeroderma, xerophthalmia, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162560\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to donepezil, piperidine derivatives, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for drugs in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162545\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Donepezil may be associated with QT prolongation and torsades de pointes; use with caution in patients at risk of prolonged cardiac repolarization (Howes 2014). Cholinesterase inhibitors may have vagotonic effects which may cause bradycardia and/or heart block in patients with or without a history of cardiac disease; syncopal episodes have been associated with donepezil. Use with caution in patients with sick-sinus syndrome, bradycardia, or conduction abnormalities. Alzheimer treatment guidelines consider bradycardia to be a relative contraindication for use of centrally active cholinesterase inhibitors (APA [Rabins 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anorexia/weight loss: May cause anorexia and/or weight loss (dose-related).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: May cause dose-related diarrhea, nausea, and/or vomiting; usually resolves in 1 to 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome: Rare cases of neuroleptic malignant syndrome (NMS) have been reported (Matsumoto 2004; Warwick 2008). Discontinuation of donepezil therapy may be necessary in patients presenting with symptoms of NMS (eg, hyperthermia, irregular pulse or blood pressure, cardiac arrhythmia, diaphoresis, muscle rigidity, mental status changes, elevated creatine phosphokinase [CPK], or unexplained high fever without additional symptoms).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rhabdomyolysis: Rare cases of rhabdomyolysis (including acute renal failure) have been reported after a few months of therapy (Sahin 2014) or in the days following therapy initiation and dose increase (Aricept Canadian product monograph 2014). Use with caution in patients with risk factors for rhabdomyolysis (eg, concomitant medications associated with rhabdomyolysis, history of muscular disorders, uncontrolled hypothyroidism, renal/hepatic impairment). Discontinuation of therapy may be necessary for marked elevation of CPK levels and/or symptoms (eg, muscle pain, tenderness or weakness, malaise, fever, dark urine) suggesting rhabdomyolysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous history or NSAID use); cholinesterase inhibitors may increase gastric acid secretion. Monitor for symptoms of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with COPD and/or asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; cholinomimetics may potentially cause generalized seizures, although seizure activity may also result from Alzheimer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction or prostatic hyperplasia; cholinomimetics may cause or worsen outflow obstructions, including possible exacerbation of BPH symptoms (APA [Rabins 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Low-weight patients: Patients weighing &lt;55 kg may experience more nausea, vomiting, and weight loss than patients &ge;55 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>\n            <i>Dosage form specific issues</i></b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspartame: Some products may contain aspartame, which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162602\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162550\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9383&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162551\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162564\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20306041\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if donepezil is excreted in breast milk. The manufacturer recommends that caution be used if administered to a nursing woman.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162553\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mental status, weight, symptoms of GI intolerance, symptoms of active or occult GI bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162544\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alzheimer's disease is characterized by cholinergic deficiency in the cortex and basal forebrain, which contributes to cognitive deficits. Donepezil reversibly and noncompetitively inhibits centrally-active acetylcholinesterase, the enzyme responsible for hydrolysis of acetylcholine. This appears to result in increased concentrations of acetylcholine available for synaptic transmission in the central nervous system.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162559\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 12 to 16 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~96%, primarily to albumin (75%) and alpha<sub>1</sub>-acid glycoprotein (21%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive hepatic metabolism via CYP2D6 and 3A4 and glucuronidation to four major metabolites (two are active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 70 hours; time to steady-state: 15 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Tablet, 10 mg: 3 hours; Tablet, 23 mg: ~8 hours; <b>Note:</b> Peak plasma concentrations almost twofold higher for the 23 mg tablet compared to the 10 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (57%; 17% as unchanged drug); feces (15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162563\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Donepezil HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $233.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $233.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Aricept Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $607.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $607.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">23 mg (30): $542.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Donepezil HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $233.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $233.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">23 mg (30): $340.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162565\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldomer (ID);</li>\n      <li>Aloxtra (ID);</li>\n      <li>Alzaimax (AR);</li>\n      <li>Alzedon (HK);</li>\n      <li>Alzepil (LB, UA);</li>\n      <li>Alzim (ID);</li>\n      <li>Alzit (PA);</li>\n      <li>Ameloss (BD);</li>\n      <li>Anepzil (VN);</li>\n      <li>Arcdone (TW);</li>\n      <li>Aricept (AE, AT, AU, BB, BD, BE, BF, BG, BH, BJ, CH, CI, CN, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LK, LR, LU, LV, LY, MA, ML, MR, MU, MW, NE, NG, NO, NZ, OM, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Aricept 23 (PH);</li>\n      <li>Aricept D (JP);</li>\n      <li>Aricept Evess (HK, ID, MY, PH, SG, TH, VN);</li>\n      <li>Aricept Evis (KR);</li>\n      <li>Aricept Soluble Film (KR);</li>\n      <li>Aricept-D (NZ);</li>\n      <li>Aripe (KR);</li>\n      <li>Aripil (IE);</li>\n      <li>Arizil (PH);</li>\n      <li>Asenta (IL);</li>\n      <li>Carencil (PE);</li>\n      <li>Concorda (NZ);</li>\n      <li>Dazolin (CO);</li>\n      <li>Demalz (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Dementile (QA, SA);</li>\n      <li>Dimenta (BD);</li>\n      <li>Donaz (IN);</li>\n      <li>Done-5 (PH);</li>\n      <li>Donebrain (ES);</li>\n      <li>Donecept (HK, IE, MT, SA, SG, TR);</li>\n      <li>Donecil (PE);</li>\n      <li>Donept (TH);</li>\n      <li>Donezel (LK, PH);</li>\n      <li>Donezil (KR, MY);</li>\n      <li>Dopezil (PH, TH);</li>\n      <li>Dopil (HR);</li>\n      <li>Dozept (IE);</li>\n      <li>Dozil (ID, LK);</li>\n      <li>Dozyl (TR);</li>\n      <li>Elzer (BD, LK);</li>\n      <li>Epalon (TW);</li>\n      <li>Eranz (AR, BR, CL, CO, MX, VE);</li>\n      <li>Labrea (BR);</li>\n      <li>Lixben (ES);</li>\n      <li>Memorin (BD);</li>\n      <li>Memorit (IL);</li>\n      <li>Miracet (KR);</li>\n      <li>Navazil (NL);</li>\n      <li>Nepes (TW);</li>\n      <li>Nepezil (BR);</li>\n      <li>Neurocept (KR);</li>\n      <li>Neutoin (KR);</li>\n      <li>Nomi-Nox (TW);</li>\n      <li>Piridon (UY);</li>\n      <li>Remecin (TW);</li>\n      <li>Rewise (TW);</li>\n      <li>Servoneks (UA);</li>\n      <li>Silvercept (KR);</li>\n      <li>Sundonnez (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tonizep 5 (TH);</li>\n      <li>Torpezil (PH);</li>\n      <li>Vastia (HK, KR);</li>\n      <li>Vencel (PY);</li>\n      <li>Yasnal (ES, HR, UA);</li>\n      <li>ZIldon (RO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aricept (donepezil) [prescribing information]. New York, NY: Pfizer; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aricept (donepezil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aricept tablets and orally disintegrating tablets (donepezil) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26918649\"></a>Chen YD, Zhang J, Wang Y, Yuan JL, Hu WL. Efficacy of cholinesterase inhibitors in vascular dementia: an updated meta-analysis. <i>Eur Neurol</i>. 2016;75(3-4):132-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/26918649/pubmed\" target=\"_blank\" id=\"26918649\">26918649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donepezil hydrochloride extended release tablets [prescribing information]. Pulaski, TN: AvKARE Inc.; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donepezil [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22915447\"></a>Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. <i>Movement Disorders</i>. 2012;27(10):1230-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/22915447/pubmed\" target=\"_blank\" id=\"22915447\">22915447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hort J, O'Brien JT, Gainotti G, et al, &ldquo;EFNS Guidelines for the Diagnosis and Management of Alzheimer&rsquo;s Disease,&rdquo; <i>Eur J Neurol</i>, 2010, 17(10):1236-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/20831773/pubmed\" target=\"_blank\" id=\"20831773\">20831773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howes LG. Cardiovascular effects of drugs used to treat Alzheimer&rsquo;s disease. <i>Drug Saf</i>. 2014;37(6):391-395.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/24777654/pubmed\" target=\"_blank\" id=\"24777654\">24777654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23949147\"></a>Ikeda M, Mori E, Kosaka K, et al; Donepezil-DLB Study Investigators. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. <i>Dement Geriatr Cogn Disord</i>. 2013;36(3-4):229-241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/23949147/pubmed\" target=\"_blank\" id=\"23949147\">23949147</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18978490\"></a>Kim YW, Kim DY, Shin JC, Park CI, Lee JD. The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury. <i>Clin Neuropharmacol.</i> 2009;32(2):63&ndash;68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/18978490/pubmed\" target=\"_blank\" id=\"18978490\">18978490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsumoto T, Kawanishi C, Isojima D, et al. Neuroleptic malignant syndrome induced by donepezil [published online January 20,, 2004]. <i>Int J Neuropsychopharmacol</i>. 2004;7(1):101-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/14731314/pubmed\" target=\"_blank\" id=\"14731314\">14731314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22829268\"></a>Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. <i>Ann Neurol</i>. 2012;72(1):41-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/22829268/pubmed\" target=\"_blank\" id=\"22829268\">22829268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28103749\"></a>O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2017;31(2):147-168. doi: 10.1177/0269881116680924.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/28103749/pubmed\" target=\"_blank\" id=\"28103749\">28103749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(12 Suppl):5-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/18340692/pubmed\" target=\"_blank\" id=\"18340692\">18340692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sahin OZ, Ayaz T, Yuce S, et al. A rare case of acute renal failure secondary to rhabdomyolysis probably induced by donepezil [published online April 27, 2014]. <i>Case Rep Nephrol</i>. 2014;2014:214359. doi: 10.1155/2014/214359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/24864216/pubmed\" target=\"_blank\" id=\"24864216\">24864216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Veterans Affairs/Department of Defense clinical practice guideline for the management of concussion/mild traumatic brain injury. <a href=\"https://www.healthquality.va.gov/guidelines/Rehab/mtbi/mTBICPGFullCPG50821816.pdf.\">https://www.healthquality.va.gov/guidelines/Rehab/mtbi/mTBICPGFullCPG50821816.pdf</a>. Published February 2016. Accessed December 20, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24984098\"></a>Velikonja D, Tate R, Ponsford J, McIntyre A, Janzen S, Bayley M; INCOG Expert Panel. INCOG recommendations for management of cognition following traumatic brain injury, part V: memory. <i>J Head Trauma Rehabil</i>. 2014;29(4):369-386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/24984098/pubmed\" target=\"_blank\" id=\"24984098\">24984098</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warwick TC, Moningi V, Jami P, et al. Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine [published online January 22, 2008].<i> Nat Clin Pract Neurol</i>. 2008;4(3):170-174. doi: 10.1038/ncpneuro0728.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/18212788/pubmed\" target=\"_blank\" id=\"18212788\">18212788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15241749\"></a>Zhang L, Plotkin RC, Wang G, Sandel ME, Lee S. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. <i>Arch Phys Med Rehabil. </i>2004;85(7):1050&ndash;1055.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/donepezil-drug-information/abstract-text/15241749/pubmed\" target=\"_blank\" id=\"15241749\">15241749</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9383 Version 234.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F162576\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F162577\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F162609\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F162581\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F162582\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15804856\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15804857\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F162555\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F162541\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F759356\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F162557\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725331\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F162616\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162548\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162560\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162545\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F162602\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162550\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F162551\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F162564\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20306041\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F162553\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162544\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F162559\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F162563\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F162565\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9383|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=donepezil-patient-drug-information\" class=\"drug drug_patient\">Donepezil: Patient drug information</a></li></ul></div></div>","javascript":null}